Cergentis
Menu

TLA technology & targeted complete NGS of genes and gene fusions in leukemia

13 March 2019Webinars

Find an alternative MRD marker, learn more about TLA and its ability to detect breakpoints at DNA level of cancer driving fusion genes. Join our webinar 13 March 2019 at 3:00PM CET (9:00AM EST) presented by our Head of Oncology Business Development, Harma Feitsma and Head of Pediatric Oncology Lab at University Children’s Hospital Zurich, Beat Schaefer.

Overview
© 2012-2020 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.